NCT00666081View on ClinicalTrials.gov

Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Cancer
Interventions
DRUG

GSK690693

Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00666081 - Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies | Biotech Hunter | Biotech Hunter